Oramed Pharmaceuticals Inc. (ORMP) Fair Value 2026

ORMP · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 4 models active

Value Trap Risk

LOW (39/100)

Quick Summary — As of 2026-08-28, Oramed Pharmaceuticals Inc. (ORMP) trades at $5.03, versus a $9.71 median fair value across its 4 active models — 93.1% above the current price. QOC: 6.3/10. Value Trap Risk: 39/100 (LOW). 4/13 models active. Within that set, the Bayesian DCF component alone returns $7.67.

Key Facts

Ticker
ORMP
Price
$5.03
Quality Score
6.3/10
Value Trap Risk
39/100
Models Active
4/13
Last Updated
Strength: CUCE Ensemble suggests +169.5% upside with 1% confidence
Risk: Limited model coverage (4/13) may reduce confidence

Is Oramed Pharmaceuticals Inc. (ORMP) Undervalued or Overvalued in 2026?

According to CirclFi’s 4-model valuation engine, Oramed Pharmaceuticals Inc. (ORMP) appears undervalued as of : the median of 4 independent fair value estimates is $9.71, 93.1% above the current price of $5.03. Estimates range from $6.77 to $13.56. ORMP scores 6.3/10 on fundamental quality and 39/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. ORMP’s +93.1% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Oramed Pharmaceuticals Inc. Stock in 2026? →

What Fair Value Does Each Model Give ORMP?

4 Intrinsic Value Models vs. Current Price ($5.03)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Low Conviction
 $7.67 +52.5%
Ensemble · Low Conviction
 $13.56 +169.5%
Unlock the Full Matrix

Access 2 additional models including Regime Cross-Sectional, RCMH-DCF.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 4 Models →

Cancel anytime · No contracts · Instant access

What Is ORMP's Fair Value Range?

Spread across 4 independent models · $6.77 to $13.56

CirclFi's 4 active models place Oramed Pharmaceuticals Inc. (ORMP) between $6.77 and $13.56 per share, a spread of 70% of the median. The median of that range — $9.71 — is the fair value CirclFi publishes for ORMP, against a current price of $5.03.

Low · Regime CrossHigh · CUCE
$6.77median $9.71$13.56
Where the range comes from
Most bearish modelRegime Cross-Sectional$6.77
Most bullish modelCUCE$13.56
Model agreement4 bullish · 0 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on ORMP, not a CirclFi price target. How each model works →

What Is Oramed Pharmaceuticals Inc. (ORMP) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Oramed Pharmaceuticals Inc.. Trading at $5.03 against an estimated intrinsic value of $9.71, 4 of 4 active models flag meaningful upside of +93.1% at the median. The most optimistic model, CUCE, places fair value at $13.56 (+169.5%), while Regime Cross — the most conservative — estimates $6.77 (+34.7%). This +134.8% gap reflects genuine analytical uncertainty about Oramed Pharmaceuticals Inc.'s intrinsic worth.

What Do the Models Say About ORMP?

4 of 13 models are currently active for ORMP. All 4 active models suggest the stock trades below fair value. Taken together, their median fair value for ORMP is $9.71 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $7.67 on its own, implying +52.5% upside from the current price. See which stocks rank higher →

How Does ORMP Rank in Biotechnology?

Among 625 Biotechnology stocks, ORMP ranks #117 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Oramed Pharmaceuticals Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is ORMP a Value Trap?

CirclFi's Value Trap algorithm assigns ORMP a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

4 of 13 models are active for Oramed Pharmaceuticals Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Oramed Pharmaceuticals Inc. scores 6.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +134.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ORMP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ORMP's 4 active models, average confidence is 16%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Oramed Pharmaceuticals Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BRTXBioRestorative Therapies, Inc.QOC 6.3PHATPhathom Pharmaceuticals, Inc.QOC 6.3CHRSCoherus Oncology, Inc.QOC 6.3LXRXLexicon Pharmaceuticals, Inc.QOC 6.3RLYBRallybio CorporationQOC 6.3NTLAIntellia Therapeutics, Inc.QOC 6.3ALDXAldeyra Therapeutics, Inc.QOC 5.2LTRNLantern Pharma Inc.QOC 4.6TRAXFirst Tracks Biotherapeutics, Inc.QOC 3.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BRTX · PHAT · CHRS · LXRX · RLYB · NTLA · ALDX · LTRN · TRAX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ORMP?

7 companies across all industries closest to ORMP’s Quality of Company score of 6.3/10.

IQiQIYI, Inc.QOC 6.3MAYSJ.W. Mays, Inc.QOC 6.3ALCOAlico, Inc.QOC 6.3ALITAlight, Inc.QOC 6.3BLCOBausch + Lomb CorporationQOC 6.3WPPWPP plcQOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: IQ · MAYS · ALCO · ALIT · BLCO · WPP · NVDA

Where Does ORMP Sit in CirclFi's Biotechnology Rankings?

ORMP is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Oramed Pharmaceuticals Inc.’s Valuation?

What is Oramed Pharmaceuticals Inc.'s intrinsic value in 2026?

CirclFi puts Oramed Pharmaceuticals Inc. (ORMP)'s intrinsic value at $9.71 — the median of 4 independent model estimates as of 2026-08-28, ranging from $6.77 to $13.56. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $7.67 on its own. The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ORMP overvalued or undervalued right now?

At $5.03, 4 of 4 active models suggest ORMP may be undervalued, while 0 indicate potential overvaluation. The median of all 4 fair value estimates is $9.71, 93.1% above the current price of $5.03 — a consensus view that ORMP is undervalued. The assessment depends on which methodology best fits Oramed Pharmaceuticals Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.3 mean for ORMP?

Oramed Pharmaceuticals Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ORMP?

CirclFi analyzes ORMP with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 4 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ORMP?

Of the 4 models currently active on ORMP, CUCE is the most bullish at $13.56 per share, and Regime Cross-Sectional is the most bearish at $6.77. CirclFi's published fair value for ORMP is the median of that range, $9.71, not either extreme. The gap between the two ends equals 70% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is ORMP a value trap in 2026?

Oramed Pharmaceuticals Inc.'s Value Trap score is 39/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 4-model valuation engine, Oramed Pharmaceuticals Inc. (ORMP) has a median fair value of $9.71 — 93.1% above the current price of $5.03 — as of 2026-08-28.” Source: circlfi.com/stock/ORMP/ · Methodology
Primary sources for this ORMP valuation
  • Financial statements: Oramed Pharmaceuticals Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001176309) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ORMP as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 4 mathematical frameworks give you clarity on ORMP.

Unlock All 4 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

2 models hidden for ORMP Unlock All 4 — $39/mo